Last reviewed · How we verify
Single Agent IV Antibiotic Therapy - MRSA
The drug is a single-agent IV antibiotic therapy for MRSA, currently marketed by West Virginia University. A key strength is the protection of its core composition through a patent expiring in 2028. The primary risk is the lack of disclosed revenue data, which may indicate limited market penetration or financial performance.
At a glance
| Generic name | Single Agent IV Antibiotic Therapy - MRSA |
|---|---|
| Also known as | daptomycin, vancomycin, ceftaroline, rifampin |
| Sponsor | West Virginia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: